Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30801866 | 0.83 | POLB (0.44) | POLBPKM | |
| SCHEMBL30801854 | 0.76 | ZDHHC9 (0.38) | KCNH2GRIN2B | |
| SCHEMBL23574126 | 0.76 | UCHL1 (0.41) | KCNH2PKM | |
| SCHEMBL23574128 | 0.76 | UCHL1 (0.41) | KCNH2PKM | |
| SCHEMBL30801878 | 0.76 | TAAR1 (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL30801824 | 0.74 | HSD11B1 (0.34) | HTR2AHTR2CHTR2B | |
| SCHEMBL30801735 | 0.74 | HTR2A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL30801792 | 0.74 | HSD11B1 (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL23419850 | 0.73 | SMN1; SMN2 (0.43) | POLBHTR6PKM | |
| Hydrochloric Acid SCHEMBL3602648 | 0.72 | SIGMAR1 (0.43) | HTR2AHTR2CHTR2BPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793997-B1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | claimed |